Corteva (CTVA) Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Corteva closed out Q4 2025 with a mixed earnings picture, narrowly beating profit expectations while falling short on revenue. The agricultural sciences company posted non-GAAP operating EPS of $0.22, edging past the $0.22 consensus estimate by 1.76%… Read more Corteva closed out Q4 2025 with a mixed earnings picture, narrowly beating profit expectations while falling short on revenue. The agricultural sciences company posted non-GAAP operating EPS of $0.22, edging past the $0.22 consensus estimate by 1.76%, but quarterly net sales of $3.91 billion trailed the $4.23 billion consensus by 7.49% and slipped 1.7% year-over-year, as seasonal timing shifts pushed volumes into adjacent quarters across both its Seed and Crop Protection segments. Beneath the headline numbers, a $610 million charge tied to a landmark litigation resolution with Bayer weighed heavily on GAAP results, producing a loss from continuing operations of $537 million. Yet that same settlement carries significant strategic value, accelerating Corteva's path to royalty neutrality by two years and potentially unlocking roughly $1 billion in cumulative earnings over the next decade. Looking ahead, management guided for 2026 operating EPS of $3.45 to $3.70 and operating EBITDA of $4 billion to $4.2 billion, even as a planned separation into two independent companies by late 2026 introduces execution risks that have already drawn some analyst scrutiny.